GlobeNewswire

PaperCut Releases Version 18.0 with Print Room, Fab Lab Capabilities

Dela

Education, professional service and commercial customers now able to manage specialty production and 3D printing capabilities under one easy-to-use solution

MELBOURNE, Australia, Feb. 14, 2018 (GLOBE NEWSWIRE) -- PaperCut, a global software company, today announced the general availability of its PaperCut MF v18.0  software, bringing specialty production printing and 3D printing under one, easy to use software solution. Admins and operators can simply manage all specialty jobs, while also taking advantage of PaperCut's powerful cost management, security and user identification features with the new Job Ticketing capability.

The update connects in-house print rooms and fab labs at educational institutions, legal organizations, local governments, commercial organizations and hospitals to PaperCut's print management system. The Job Ticketing capability allows operators to accept specialty and 3D printing job submissions, such as laser cutting and prototype production, and track them through the production process while communicating the status to the requesting user.

"Until now, the lack of connection between our customers' general and specialty printing solutions - such as print rooms and 3D fab labs - has been a burden that cost them both time and money," said Chris Dance, co-founder and CEO of PaperCut. "To solve these problems, we've created a simple solution that will improve their specialty printing controls, security and payment options."

Because this feature falls under the same software individuals use to manage general office printing, users don't have to set up a separate profile or be re-authenticated to submit a print request, track its progression and flag questions or last-minute changes to the operator. This allows operators to spend less time managing processes-which are often manual and time-consuming-and more time driving adoption of their services and delivering high quality products for their customers.

Previously, organizations needing specialty prints lack affordable or efficient options-or both-to produce and manage jobs. Businesses would either have to use tedious, manual approaches to tracking and management, or purchase expensive software solutions limited in scope.

"The need for specialty print production is only increasing for organizations, especially universities," said Andy Slawetsky, President of Industry Analysts, Inc. "This market barely existed five years ago. Since then, there's been a rapid increase in demand resulting in a high unmet need for specialty print jobs to be managed and tracked under a unified capacity."

In addition to increased integration and workflow efficiency, the v18.0 release:

  • Reduces the need to purchase additional software packages for the print room
  • Supports all document formats and fonts on customers' personal, work and mobile devices.
  • Leverages customers' existing user permissions and accounting environment, charging for a job at any point straight back to their account.
  • Enables end users to submit a print room or 3D job through the streamlined web interface.
  • Builds a "personal touch" into the technology print room customers love, allowing for direct operator-customer communication and consistent updates on order progress.

Following PaperCut's true vendor-neutral approach, PaperCut MF v18.0 additional embedded solutions and updates have been made across a breadth of MFD devices, ensuring the platform stays up and running in conjunction with manufacturer progress. For full details on interoperability and product specs, please review the release notes, accessible here.

Availability

PaperCut MF v18.0 is now available to existing and future customers and partners. Pricing is licensed per print room as one standard product, with education and commercial customers having access to a single price exclusively as a feature of PaperCut.

About PaperCut Software
Around the world, workplaces are wrestling with printing costs and print management complexity. PaperCut is solving those problems, one workplace at a time. Since 1998, PaperCut has helped 50 million users in 175 countries save trillions of pages of paper. With PaperCut in their print environment, IT managers solve their nagging print problems once and for all. How? Its two software solutions - PaperCut MF and PaperCut NG - are cross-platform and vendor neutral. That means they work with any printer and any operating system. Plus, both solutions feature ground-breaking technology such as mobility print, secure print release, and rich reporting tools. Businesses of all shapes, sizes and industry benefit from the control, security and financial and environmental savings that PaperCut software was built for. Learn more at www.papercut.com.

Media Contact
Morgann Dulle
10Fold Communications for PaperCut
papercut@10fold.com
+1 (479) 586-1377




This announcement is distributed by Nasdaq Corporate Solutions on behalf of Nasdaq Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: Papercut Services North America LLC via Globenewswire

Om

GlobeNewswire



Följ GlobeNewswire

Abonnera på våra pressmeddelanden.

Senaste pressmeddelandena från GlobeNewswire

Arcoma AB: Investerarmöten våren 201915.2.2019 08:46:00Pressmeddelande

15 februari 2019 PRESSRELEASE Arcoma har som ambition att fortsätta öka sitt aktieägarfokus och kontinuerligt förbättra kommunikationen med aktieägare. Under våren 2019 kommer Arcoma medverka på flertalet investerarmöten där aktuella händelser och aktiviteter presenteras. Här ges en ökad inblick i bolagets vision och strategier samt en möjlighet till att ställa frågor till bolagets ledning. SvD Börsplus Temadag "Dubblare" Dag, tid och plats: 5 mars, kl. 13.00, GT 30, Grev Turegatan 30, Stockholm Stockholm Corporate Finance Life Science event Dag, tid och plats: 14 mars, kl. 07.30, Berns, Kammarsalen, Stockholm Redeyes Medtech & Diagnostics event Dag, tid och plats: 14:e maj, Redeye, Mäster Samuelsgatan 42, Stockholm För ytterligare information, vänligen kontakta: Arcomas VD Jesper Söderqvist, Telefon: +46 470 70 69 81, E-mail: jesper.soderqvist at arcoma.se Om Arcoma Arcoma, med lång erfarenhet av branschen, är en ledande leverantör av integrerade digitala röntgensystem med hög kvalite

Corline Biomedical AB: Första patient doserad med Renaparin®15.2.2019 08:42:00Pressmeddelande

Corline Biomedical AB ("Corline" eller "Bolaget") meddelar idag att man inkluderat första patienten i fas 1-studien RENAPAIR 01. Patienten inkluderades vid transplantationsavdelningen på Uppsala Akademiska sjukhus. Renaparin® är en produkt under utveckling för att förbättra njurtransplantation. I Corlines studie RENAPAIR 01 utvärderas produkten med avseende på tolerabilitet och säkerhet. Studien öppnades för patientrekrytering i slutet av 2018 och första patient är nu doserad och inkluderad i studien. Totalt skall 18 patienter rekryteras och när de 4 första patienterna är utvärderade i Uppsala, öppnas också Karolinska Universitetssjukhuset i Huddinge för rekrytering till studien. Henrik Nittmar, VD i Corline Biomedical AB, kommenterar "Det händer mycket i Corline för tillfället och alla arbetar hårt för att målbilden i bolaget skall uppfyllas. Det gäller såväl vår interna organisation som våra externa samarbetspartners. Därför är det extra roligt när vi når avgörande milstolpar i utvec

Corline Biomedical AB: Rekryterar Lars Olsson som Head of CMC14.2.2019 12:44:00Pressmeddelande

Corline Biomedical AB ("Corline" eller "Bolaget") meddelar idag att man rekryterat Lars Olsson till den nyinrättade tjänsten som Head of CMC (Chemistry, Manufacturing & Control). Lars Olsson hade tidigare samma tjänst hos Wilson Therapeutics AB, som under 2018 förvärvades av amerikanska Alexion. Lars Olsson kommer att ansvara för Corlines samtliga aktiviteter inom tillverkning och kontroll relaterat till bolagets läkemedelsprodukter, med särskilt fokus på Renaparin® inför kommande fas 2- och fas 3-utveckling. I slutet av 2018 meddelade Corline att patientrekryteringen startar i bolagets fas 1-studie RENAPAIR 01, där produkten Renaparin®, som är under utveckling för att förbättra utfallet av njurtransplantation, utvärderas med avseende på tolerabilitet och säkerhet. Därmed tog en ny utvecklingsfas vid i bolaget i vilken alltmer resurser fokuseras på att förbereda den fortsatta kliniska utvecklingen av produkten genom fas 2 och fas 3 i syfte att slutligen kunna registrera produkten för k

Arcoma AB: Canon och Arcoma tecknar distributörsavtal för Turkiet14.2.2019 10:38:00Pressmeddelande

14 februari 2019 Canon Medical Systems i Turkiet och Arcoma har tecknat ett distributörsavtal som gör att Canon kommer att kunna sälja Arcomas produkter i Turkiet från och med den 15 februari 2019. Canon är sedan tidigare återförsäljare för Arcomas produkter i Nordamerika och utvalda länder i Europa. Detta samarbete utökas nu till Turkiet som är det första land i Canons Asien organisation att välja Arcoma som en formell partner. "Att vi stärker och formaliserar samarbetet med Canon även i Turkiet är ännu ett erkännande av Arcoma som leverantör av högkvalitativa röntgensystem. Canon i Turkiet förbereder ett flertal större upphandlingar till sjukhus där Arcomas lösningar ingår. Avtal som detta ingår i Arcomas strategi att utöka med nya försäljningskanaler och att expandera till nya länder för att skapa framtida tillväxt." kommenterar Arcomas VD, Jesper Söderqvist. För ytterligare information, vänligen kontakta: Arcomas VD Jesper Söderqvist, Telefon: +46 470 70 69 81, E-mail: jesper.soder

Karolinska Development's portfolio company OssDsign raises SEK 64m and aims for listing on Nasdaq First North12.2.2019 09:00:00Pressmeddelande

STOCKHOLM, February 12, 2019. Karolinska Development's portfolio company OssDsign announces today the closing of a private placement of SEK 64 million. Swedish private investors and the French investment management company Alto Invest have taken part in the private placement. OssDsign will now begin the process towards a listing on Nasdaq First North in 2019. The proceeds from the private placement will be used for continued sales expansion in Europe and the US of OssDsign regenerative implant solutions for improved healing of bone defects. Moreover, funds will be used for entering new markets, primarily preparing for market introduction in Japan where the company in parallel to the regulatory process will initiate pre marketing activities. With ethical committee approval already in place, leading surgeons in Japan can start building experience with the OssDsign technology prior to regulatory approval and launch. OssDsign prepares for a listing on Nasdaq Stockholm First North in 2019.

Karolinska Development's portfolio company OssDsign raises SEK 64m and aims for listing on Nasdaq First North12.2.2019 09:00:00Pressmeddelande

STOCKHOLM, February 12, 2019. Karolinska Development's portfolio company OssDsign announces today the closing of a private placement of SEK 64 million. Swedish private investors and the French investment management company Alto Invest have taken part in the private placement. OssDsign will now begin the process towards a listing on Nasdaq First North in 2019. The proceeds from the private placement will be used for continued sales expansion in Europe and the US of OssDsign regenerative implant solutions for improved healing of bone defects. Moreover, funds will be used for entering new markets, primarily preparing for market introduction in Japan where the company in parallel to the regulatory process will initiate pre marketing activities. With ethical committee approval already in place, leading surgeons in Japan can start building experience with the OssDsign technology prior to regulatory approval and launch. OssDsign prepares for a listing on Nasdaq Stockholm First North in 2019.

I vårt pressrum kan du läsa de senaste pressmeddelandena, få tillgång till pressmaterial och hitta kontaktinformation.

Besök vårt pressrum